Technological innovation drives the vigorous development of new economic industries. Recently, the globally renowned third-party data mining and analysis organization iiMedia Research released the “Research Report on China’s New Economy Unicorn Benchmark Enterprise in 2022”. Henglu Bio successfully made it onto the “2022 China New Economy Future Unicorn Enterprise TOP100 List” due to its technological innovations and digital applications in the field of synthetic biology.

This list focuses on the top 100 unicorns, quasi-unicorns, and future unicorns in China's new economic sector for 2022. Through a comprehensive evaluation of strength and development trends, it showcases the fresh energy and growth potential within the new economic industry, being hailed as a "barometer for investment in the new economy sector."

The report highlights that unicorn companies, as leaders in transformation and typical representatives of the new economy, are characterized by explosive growth and disruptive innovation. The companies recognized in this list demonstrate strong development momentum and are important engines driving the high-quality development of the new economy, becoming the core forces for the steady and long-term improvement of China's economy.

Compared to last year’s ranking of the top 200, this Top 100 list features fewer companies but is more representative of the industry. In particular, it has strengthened evaluation criteria regarding companies’ technological innovation, product innovation, marketing innovation, business growth, development potential, and core competitiveness.

After several rounds of evaluations, the top 100 companies stood out among many high-performing enterprises, becoming benchmark companies across various fields in 2022. Shandong Henglu Biotechnology Co., Ltd. was recognized for its cutting-edge technological innovations in synthetic biology and its potential in future market development.

Innovation is the essential characteristic and core competitiveness of unicorn companies. In recent years, Henglu Bio has continuously increased its investment in scientific research, enhancing its innovation capabilities. By leveraging its self-developed "biological enzymatic method" technology path and a novel process that is pioneering both domestically and internationally, Henglu Bio has made continuous breakthroughs in the research of green advanced biological manufacturing technologies and the industrialization of functional active substances. The raw materials produced include HMOs series products, Salidroside series products, tyrosol, hydroxytyrosol, as well as small molecule active peptide products like sea cucumber oligopeptides and sea cucumber saponins, which can be widely used in the fields of food, cosmetics, health food, special medical formula foods, and biomedicine.

Currently, Henglu Bio has established the Henglu Smart AI Computing Cloud Platform, which employs software engineering techniques to implement a comprehensive rational design of industrial microorganisms, using AI technology to simulate the process of high-throughput screening of synthetic biological strains, thus accelerating the entire process from new product development to large-scale production. With the initial completion of its domestic and international patent layout, Henglu Biotechnology has established a higher technical barrier, carving out a distinct technological path that differs from the U.S. and European approaches, effectively addressing the “bottleneck” technical issues faced by China.

Being included in the “2022 China New Economy Future Unicorns” Top 100 list showcases the robust vitality of technological innovation in synthetic biology companies. Henglu Bio, with its green, energy-efficient, and high-tech processes, merges cutting-edge technological innovation with refined and personalized services, becoming an inexhaustible driving force for the company’s development, as it strides towards becoming a stronger and higher-tech innovative unicorn enterprise.